Oncology Certified Nurse (OCN) Test 2025 – 400 Free Practice Questions to Pass the Exam

The MVAC chemotherapy regimen, which stands for Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, has been shown to significantly improve survival outcomes when used in conjunction with surgery for bladder cancer. This regimen is well-established in the treatment of muscle-invasive bladder cancer and has demonstrated increased efficacy in clinical studies, effectively doubling survival rates compared to surgery alone.

MVAC acts by attacking cancer cells at multiple stages of their lifecycle, which enhances the overall effectiveness of treatment. The combination of these agents provides a synergistic effect, targeting rapidly dividing tumor cells and minimizing the likelihood of cancer recurrence. The ability of MVAC to reduce tumor burden before surgical intervention can also improve surgical outcomes and increase the chances for a successful recovery.

In contrast, the other regimens listed are not primarily used in the context of bladder cancer treatment. For example, Carboplatin is generally utilized for various other cancers and does not specifically target bladder cancer as effectively as MVAC does. ATRA (All-Trans Retinoic Acid) is primarily associated with acute promyelocytic leukemia and has no role in bladder cancer therapy, while CAB, which typically refers to a different combination of agents or may not be well defined in the context of bladder